Last reviewed · How we verify
Transfusion
At a glance
| Generic name | Transfusion |
|---|---|
| Also known as | non applicable |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy (NA)
- Monochorial-diamniotic Pregnancies Complicated With a Twin-to-twin Syndrome
- Canadian Critical Care Comparative Effectiveness Platform (PHASE3)
- Complement (C1q) Binding to HLA Antibodies in a Solid-phase Immunoassay and Clinical Effect on Platelet Transfusion
- Study of Transfusion-Transmitted Infections
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transfusion CI brief — competitive landscape report
- Transfusion updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI